OBJECTIVE: To estimate whether elevations of complement C3a early in pregnancy are predictive of the subsequent development of adverse pregnancy outcomes. METHODS: A plasma sample was obtained from each enrolled pregnant woman before 20 weeks of gestation. The cohort (n=1,002) was evaluated for the development of adverse pregnancy outcomes defined as hypertensive diseases of pregnancy (gestational hypertension or preeclampsia), preterm birth (before 37 weeks of gestation), premature rupture of the membranes, pregnancy loss (during the embryonic and fetal period), intrauterine growth restriction, and the composite outcome of any adverse outcome. RESULTS: One or more adverse pregnancy outcomes occurred in 211 (21%) of the cohort. The mean levels (ng/mL) of C3a in early pregnancy were significantly (P=<.001) higher among women with one or more adverse outcomes (858±435) compared with women with an uncomplicated pregnancy (741±407). Adjusted for parity and prepregnancy body mass index, women with levels of C3a in the upper quartile in early pregnancy were three times more likely to have an adverse outcome later in pregnancy compared with women in the lowest quartile (95% confidence interval, 1.8-4.8; P<.001). The link between early elevated C3a levels and adverse pregnancy outcomes was driven primarily by individual significant (P<.05) associations of C3a with hypertensive diseases of pregnancy, preterm birth, and premature rupture of the membranes. CONCLUSION: Elevated C3a as early as the first trimester of pregnancy is an independent predictive factor for adverse pregnancy outcomes, suggesting that complement-related inflammatory events in pregnancy contribute to the subsequent development of poor outcomes at later stages of pregnancy. LEVEL OF EVIDENCE: II.
OBJECTIVE: To estimate whether elevations of complement C3a early in pregnancy are predictive of the subsequent development of adverse pregnancy outcomes. METHODS: A plasma sample was obtained from each enrolled pregnant woman before 20 weeks of gestation. The cohort (n=1,002) was evaluated for the development of adverse pregnancy outcomes defined as hypertensive diseases of pregnancy (gestational hypertension or preeclampsia), preterm birth (before 37 weeks of gestation), premature rupture of the membranes, pregnancy loss (during the embryonic and fetal period), intrauterine growth restriction, and the composite outcome of any adverse outcome. RESULTS: One or more adverse pregnancy outcomes occurred in 211 (21%) of the cohort. The mean levels (ng/mL) of C3a in early pregnancy were significantly (P=<.001) higher among women with one or more adverse outcomes (858±435) compared with women with an uncomplicated pregnancy (741±407). Adjusted for parity and prepregnancy body mass index, women with levels of C3a in the upper quartile in early pregnancy were three times more likely to have an adverse outcome later in pregnancy compared with women in the lowest quartile (95% confidence interval, 1.8-4.8; P<.001). The link between early elevated C3a levels and adverse pregnancy outcomes was driven primarily by individual significant (P<.05) associations of C3a with hypertensive diseases of pregnancy, preterm birth, and premature rupture of the membranes. CONCLUSION: Elevated C3a as early as the first trimester of pregnancy is an independent predictive factor for adverse pregnancy outcomes, suggesting that complement-related inflammatory events in pregnancy contribute to the subsequent development of poor outcomes at later stages of pregnancy. LEVEL OF EVIDENCE: II.
Authors: Fadi Fakhouri; Lubka Roumenina; François Provot; Marion Sallée; Sophie Caillard; Lionel Couzi; Marie Essig; David Ribes; Marie-Agnès Dragon-Durey; Frank Bridoux; Eric Rondeau; Veronique Frémeaux-Bacchi Journal: J Am Soc Nephrol Date: 2010-03-04 Impact factor: 10.121
Authors: Anne M Lynch; James R Murphy; Tim Byers; Ronald S Gibbs; Margaret C Neville; Patricia C Giclas; Jane E Salmon; V Michael Holers Journal: Am J Obstet Gynecol Date: 2008-01-25 Impact factor: 8.661
Authors: A J Wilcox; C R Weinberg; J F O'Connor; D D Baird; J P Schlatterer; R E Canfield; E G Armstrong; B C Nisula Journal: N Engl J Med Date: 1988-07-28 Impact factor: 91.245
Authors: Anne M Lynch; Brandie D Wagner; Patricia C Giclas; Nancy A West; Ronald S Gibbs; V Michael Holers Journal: Am J Reprod Immunol Date: 2015-10-29 Impact factor: 3.886
Authors: Jean F Regal; Megan E Strehlke; Jenna M Peterson; Cameron R Wing; Jordan E Parker; Noel Fernando Nieto; Lynne T Bemis; Jeffrey S Gilbert; Sherry D Fleming Journal: Mol Immunol Date: 2016-08-30 Impact factor: 4.407
Authors: Jennifer L Sones; Audrey A Merriam; Angelina Seffens; Dex-Ann Brown-Grant; Scott D Butler; Anna M Zhao; Xinjing Xu; Carrie J Shawber; Jennifer K Grenier; Nataki C Douglas Journal: FASEB J Date: 2018-01-08 Impact factor: 5.191
Authors: M Banadakoppa; M S Chauhan; D Havemann; M Balakrishnan; J S Dominic; C Yallampalli Journal: Clin Exp Immunol Date: 2014-09 Impact factor: 4.330
Authors: Anne M Lynch; Brandie D Wagner; Robin R Deterding; Patricia C Giclas; Ronald S Gibbs; Edward N Janoff; V Michael Holers; Nanette F Santoro Journal: Am J Obstet Gynecol Date: 2015-11-11 Impact factor: 8.661
Authors: Jude J McElroy; Courtney E Gutman; Christian M Shaffer; Tamara D Busch; Hilkka Puttonen; Kari Teramo; Jeffrey C Murray; Mikko Hallman; Louis J Muglia Journal: Hum Genet Date: 2013-04-17 Impact factor: 4.132
Authors: Kathryn E Lillegard; Alex C Johnson; Sarah J Lojovich; Ashley J Bauer; Henry C Marsh; Jeffrey S Gilbert; Jean F Regal Journal: Mol Immunol Date: 2013-05-15 Impact factor: 4.407